Selection of blockbuster announcements

1. Geely Automobile: plans to set up a joint venture company with Renault

$GEELY AUTO (00175.HK)$It was announced that on November 8, 2022 (non-trading hours), the company entered into a framework agreement with Geely Holdings and Renault, according to which the parties proposed to establish a joint venture company. The aim is to integrate the expertise and advantages of each contractor in the internal combustion engine, hybrid and plug-in hybrid assembly and transmission business and related technologies. Under the framework agreement, Geely Holdings and Geely Automobile, as one party, and Renault as the other, will each tentatively have a 50 per cent interest in the proposed joint venture.

2. Baozun Inc: has signed an agreement to acquire the business of Gap Greater China

$BAOZUN-W (09991.HK)$It will announce that it will acquire Gap's Greater China business in an all-cash transaction. At present, the agreement has been signed, the consideration of the equity transaction is US $40 million, the total amount of the final adjustment of the agreement is no more than US $50 million, and the acquisition is expected to be completed in the first half of 2023. According to the acquisition process and relevant laws and regulations, the transaction procedure will be formally completed after the approval of the relevant departments.

3. China Petroleum & Chemical Corp oil suit: won the bid for the $830 million project of Kuwait Oil Company.

$SINOPEC SSC (01033.HK)$Recently, China Petroleum & Chemical Group International Petroleum Engineering Co., Ltd., a wholly owned subsidiary of the company, won the bid for 14 development well drilling and workover rigs and one deep well drilling rig project of Kuwait Petroleum Company (KOC), with a contract period of 5 years, with a total amount of about 830 million US dollars. The total amount of the winning bid is equivalent to about 5.988 billion yuan, accounting for about 8.61% of the company's 2021 operating income under Chinese accounting standards.

4. Mega Ophthalmology-B: an exclusive distribution agreement was reached for the commercial production of TONO-i for self-measurement of intraocular pressure in Greater China.

$ZHAOKE OPHTH-B (06622.HK)$Announced that the company and C&VTech have reached an exclusive distribution agreement for TONO-i. C&VTech is a leader in the development of medical devices for the diagnosis, treatment and prevention of glaucoma. Under the terms of the agreement, the company has the exclusive right to register, import, promote, distribute, market and sell TONO-i in Greater China.

5. CNOOC Petroleum Chemistry: China Securities Regulatory Commission approves the application for full circulation of some unlisted H shares of the company.

$CHINA BLUECHEM (03983.HK)$According to the announcement, the company has recently been formally approved by the China Securities Regulatory Commission to implement its application for full circulation of H shares. According to this, American Yunan Company (Trammo,Inc.) 25000122 unlisted shares of the company are approved to be converted into H shares of the company and listed on the Stock Exchange. After conversion and listing, the total number of H shares of the company will be 1796000122 shares. The approval is valid for 12 months from October 31, 2022.

6. Dongyangguang medicine: Mendong insulin 30 injection has been approved to be put on the market.

$YiChang HEC ChangJiang Pharmaceutical (01558.HK)$According to the announcement, Mendong Insulin 30 injection, a product independently researched and developed by the company, has been approved by the State Drug Administration of China and approved for listing. The product is a premixed insulin containing 30% soluble asparagus insulin and 70% protamine aspartate insulin. The product is suitable for the treatment of diabetes, can be injected before meals, its glycosylated hemoglobin (HbA1c) standard rate is higher, it can better control fasting and postprandial blood glucose at the same time, and has obvious advantages in improving blood glucose control, reducing the risk of hypoglycemia, improving compliance and saving medical costs, and is more suitable for high-risk patients with impaired hypoglycemia perception. The product is a biological product drug approved by the group on the market, with a cumulative R & D cost of about 116 million yuan.

Financial data

Jinhui Holdings (09993): revenue in the first nine months was 22.856 billion yuan, down 12.07% from the same period last year; net profit from home was 1.489 billion yuan, down 27.86% from the same period last year

The net profit from continuing operations in the first three quarters of FIT HON TENG (06088) reached US $135 million, an increase of 199.76% over the same period last year.

Mongolia Energy (00276): 826000 tons of coking coal were sold in the medium term, and revenue increased to HK $1.886 billion

Silk Road Energy (08250) earned about HK $988 million in the first quarter, a year-on-year increase of about 42 times.

Operation data

The total contract sales of Baolong Real Estate (01238) in the first 10 months reached 34.687 billion yuan.

Poly Real Estate Group (00119) achieved a total contract sales of 37 billion yuan in the first 10 months, a decrease of 18% over the same period last year.

Contract sales of Hongyang Real Estate (01996) in October is 3.709 billion yuan.

The advance sale of Hop King Pacific Group (01813) was 4.22 billion yuan in October.

Increase and decrease holdings

Longfor Group (00960) and his controlling shareholders bought another $5 million of preferred notes issued by the company.

Investment and operation

Mega Ophthalmology-B (06622): phase II clinical trial with ZKY001 for the treatment of TPRK, phase II clinical trial for pterygium and IIT for NK completed patient enrollment

Jinke Services (09666): Boyu Capital's offer has been approved by antitrust

Zai Lab Limited-B (09688): the abbreviation of Chinese and English shares will no longer be marked "B".

Repurchase cancellation

China Petroleum & Chemical Corporation (00386) buys back 29.294 million H shares and 12 million A shares on November 8th

AIA Group Limited (01299) spent HK $48.8103 million to buy back 720800 shares on November 8th.

Health International Medical (03886) buyback 20 million shares at a cost of HK $6.9012 million

Innovation Qizhi (02121) spent HK $21.7549 million to buy back 991900 shares on November 8th

Swire AG A (00019) spent HK $16.973 million to repurchase 303000 shares on November 8th

China Literature (00772) spent HK $7.005 million to buy back 300000 shares on November 8th.

Haier Smart Home (06690) spent HK $12.07 million to buy back 550000 shares on November 8th.

Yum China (09987) spent about US $1 million to buy back 20, 000 shares on November 7.

Debt financing

Federal Pharmaceutical (03933): up to HK $1.1 billion term loan line granted

China Construction Bank Corporation (00939) completed the issuance of 40 billion yuan of secondary capital bonds